Neurizon Therapeutics (FRA:ECQ0) Moat Score: 2/10 (As of Jul. 05, 2026)


What is Neurizon Therapeutics Moat Score?

Neurizon Therapeutics FRA:ECQ0 Moat Score is 2 as of Jul. 05, 2026. The stock has 2 warning signs investors should review. Among 1,395 Biotechnology companies, Neurizon Therapeutics ranks better than 58.28% on this metric.

Neurizon Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Neurizon Therapeutics has No Moat: Neurizon Therapeutics Ltd lacks market leadership and significant intellectual property. The company does not have strong customer loyalty or regulatory barriers, resulting in no discernible competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Neurizon Therapeutics might have No Moat - Very weak/transient advantages.

Neurizon Therapeutics  (FRA:ECQ0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Neurizon Therapeutics Moat Score Related Terms

FRA:ECQ0 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Neurizon Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurizon Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurizon Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Neurizon Therapeutics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Neurizon Therapeutics (FRA:ECQ0) has a Moat Score of 2 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Neurizon Therapeutics ranks #582 out of 1395 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Neurizon Therapeutics' Moat Score too high?
Neurizon Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Neurizon Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Neurizon Therapeutics ranks #582 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint.
How does Neurizon Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurizon Therapeutics ranks #582 out of 1395 companies for Moat Score. This puts Neurizon Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Neurizon Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurizon Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurizon Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurizon Therapeutics stock overvalued right now?
Neurizon Therapeutics (FRA:ECQ0) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Neurizon Therapeutics (FRA:ECQ0), the current Moat Score is 2 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurizon Therapeutics Business Description

Other Exchanges ECQ0:GermanyNUZ:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).